NA
EDIT icon

NewEdge Advisors’s Editas Medicine EDIT Stock Holding History

NewEdge Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.2K Hold
1,295
– – ﹤0.01% 3766
2026
Q1 		$3.2K Hold
1,295
– – ﹤0.01% 3694
2025
Q4 		$2.65K Hold
1,295
– – ﹤0.01% 3830
2025
Q3 		$4.49K Hold
1,295
– – ﹤0.01% 3567
2025
Q2 		$2.85K Hold
1,295
– – ﹤0.01% 3549
2025
Q1 		$1.5K Hold
1,295
– – ﹤0.01% 3562
2024
Q4 		$1.65K Sell
1,295
-210
-14% -$535 ﹤0.01% 3482
2024
Q3 		$5.13K Sell
1,505
-50
-3% -$218 ﹤0.01% 3162
2024
Q2 		$7.26K Sell
1,555
-325
-17% -$1.83K ﹤0.01% 2973
2024
Q1 		$13.9K Hold
1,880
– – ﹤0.01% 2754
2023
Q4 		$19K Hold
1,880
– – ﹤0.01% 2581
2023
Q3 		$14.7K Sell
1,880
-300
-14% -$2.57K ﹤0.01% 2458
2023
Q2 		$17.9K Sell
2,180
-80
-4% -$697 ﹤0.01% 2410
2023
Q1 		$16.4K Sell
2,260
-482
-18% -$4.29K ﹤0.01% 2404
2022
Q4 		$6.96K Buy
+2,742
New +$30.1K ﹤0.01% 2479

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

NewEdge Advisors's EDIT Position: Q2 2026 in Review

NewEdge Advisors held its Editas Medicine (EDIT) position steady in Q2 2026 at 1,295 shares worth $4.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3766.

NewEdge Advisors first reported a position in EDIT in Q4 2022 and has held it in 15 quarters since. The position peaked at $19K in Q4 2023. 214 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • NewEdge Advisors held 1,295 shares of Editas Medicine worth $4.2K as of Q2 2026.
  • NewEdge Advisors left its Editas Medicine share count unchanged in Q2 2026.
  • Editas Medicine made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #3766 holding.
  • NewEdge Advisors first reported a position in Editas Medicine in Q4 2022 and has held it in 15 quarters since.
  • NewEdge Advisors's Editas Medicine position peaked at $19K in Q4 2023.
  • 214 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.